Related Experiment Videos
Chronic active hepatitis associated with diclofenac sodium therapy
The British Journal of Clinical Practice
|March 1, 1989
Summary
Diclofenac sodium can cause liver damage. A patient developed chronic active hepatitis from diclofenac sodium, which continued even after stopping the medication, a previously unreported outcome.
Area of Science:
- Hepatology
- Pharmacology
- Internal Medicine
Background:
- Diclofenac sodium is a non-steroidal anti-inflammatory drug (NSAID) derived from phenylacetic acid.
- While generally safe, NSAIDs like diclofenac sodium can cause asymptomatic liver function abnormalities.
- Severe drug-induced hepatitis is a rare but known adverse effect of diclofenac sodium.
Observation:
- A case study details a patient who developed chronic active hepatitis.
- The hepatitis occurred after six months of continuous diclofenac sodium therapy.
- The liver condition persisted and progressed despite the discontinuation of diclofenac sodium.
Findings:
- This case presents a previously unreported progression of diclofenac sodium-induced hepatitis.
- Chronic active hepatitis developed and continued post-drug withdrawal.
- Diclofenac sodium's potential for persistent liver injury is highlighted.
Implications:
- Highlights the potential for diclofenac sodium to induce severe and persistent liver injury.
- Suggests the need for vigilant monitoring of liver function in patients on long-term diclofenac sodium therapy.
- Underscores the importance of considering drug-induced liver injury in persistent hepatitis cases.